Journal Mobile Options
Table of Contents
Vol. 42, No. 2, 2000
Issue release date: July 2000
Neuropsychobiology 2000;42:58–61

Aggressive Behavioral Characteristics and Endogenous Hormones in Women with Bulimia nervosa

Cotrufo P. · Monteleone P. · d’Istria M. · Fuschino A. · Serino I. · Maj M.
aInstitute of Psychiatry and bDepartment of Fisiologia Umana and Funzioni Biologiche Integrate ‘F. Bottazzi’, University of Naples SUN, Naples, Italy

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Increased aggressiveness frequently occurs in patients with bulimia nervosa (BN), but its neurobiological correlates have been poorly investigated. In this study, we investigated possible relationships between such clinical measure and blood levels of endogenous hormones in patients with BN. Morning plasma levels of testosterone, 17β-estradiol, prolactin (PRL) and cortisol were measured in 33 bulimic women and 22 healthy female controls. The eating-related psychopathology, depression and aggressiveness were rated by specific psychometric scales. Bulimic patients showed decreased plasma levels of PRL and 17β-estradiol, and increased concentrations of cortisol and testosterone. Moreover, patients scored higher than healthy controls on rating scales assessing eating-related psychopathology, depressive symptoms and aggressiveness. A significant positive correlation was found between testosterone plasma levels and aggressiveness in patients but not in controls. These findings suggest that in BN, increased plasma levels of testosterone may play a role in the modulation of aggressiveness.

Copyright © 2000 S. Karger AG, Basel

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Cooper PJ, Fairburn CG: The depressive symptoms of bulimia nervosa. Br J Psychiatry 1986;148:268–274.
  2. Pigott TA, Altemus M, Rubenstein CS, Hill JL, Bihari K, L’Hereux F, Bernstein S, Murphy DL: Symptoms of eating disorders in patients with obsessive-compulsive disorder. Am J Psychiatry 1991;148:1552–1557.
  3. Wolfe BE, Jimerson DC, Levine JM: Impulsivity ratings in bulimia nervosa: Relationship to binge eating behaviors. Int J Eat Disord 1994;15:289–292.
  4. Waller DA, Sheinberg AL, Gullion C, Moeller FG, Cannon DS, Petty F, Hardy DW, Orsulak P, Rush AJ: Impulsivity and neuroendocrine response to buspirone in bulimia nervosa. Biol Psychiatry 1996;39:371–374.
  5. Monteleone P, Brambilla F, Bortolotti F, Ferraro C, Maj M: Plasma prolactin response to d-fenfluramine is blunted in bulimic patients with frequent binge episodes. Psychol Med 1998;28:975–983.
  6. Coccaro EF: Impulsive aggression and central serotonergic system function in humans: An example of a dimensional brain-behavior relationship. Int J Psychopharmacol 1992;7:3–12.
  7. Albert DJ, Walsh ML, Jonik RH: Aggression in humans: What is its biological foundation? Neurosci Biobehav Rev 1993;17:405–425.
  8. World Health Organization: Composite International Diagnostic Interview. Geneva, WHO, 1987.
  9. Andreasen NC, Endicott J, Spitzer RL, Winokur G: The family history method using diagnostic criteria: Reliability and validity. Arch Gen Psychiatry 1977;34:1229–1235.
  10. Garner DL, Olmstead MP, Polivy J: Development and validation of a multidimensional eating disorders inventory for anorexia nervosa and bulimia. Int J Eat Disord 1983;2:15–35.
  11. Henderson M, Freeman CPL: A self-rating scale for bulimia: The Bite. Br J Psychiatry 1987;150:18–24.
  12. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
  13. Buss AH, Durkee A: An inventory for assessing different kinds of hostility. J Consult Psychol 1957;21:343–349.
  14. D’Istria M, Del Rio G, Botte V, Chieffi G: Radioimmunoassay of testosterone, 17β-estradiol and estrone in the male and female plasma of Rana esculenta during sexual cycle. Steroids Lipids Res 1974;5:42–48.

    External Resources

  15. Brewerton TD, Mueller EA, Lesem MD, Brandt HA, Querray B, George DT, Murphy DL, Jimerson DC: Neuroendocrine responses to m-chlorophenylpiperazine and L-tryptophan in bulimia. Arch Gen Psychiatry 1992;49:852–861.
  16. Jimerson DC, Wolfe BE, Metzger ED, Finkelstein DM, Cooper TB, Levine JM: Decreased serotonin function in bulimia nervosa. Arch Gen Psychiatry 1997;54:529–534.
  17. Levitan RD, Kaplan AS, Joffe RT, Levitt AJ, Brown GM: Hormonal and subjective responses to intravenous meta-chlorophenylpiperazine in bulimia nervosa. Arch Gen Psychiatry 1997;54:521–527.
  18. Mortola JF, Rasmussen DD, Yen SSC: Alterations of the adrenocorticotropin-cortisol axis in normal weight bulimic women: Evidence for a central mechanism. J Clin Endocrinol Metab 1989;68:517–522.

    External Resources

  19. Levy AB: Neuroendocrine prolife in bulimia nervosa. Biol Psychiatry 1989;25:98–109.
  20. Sundblad C, Bergman L, Eriksson E: High levels of free testosterone in women with bulimia nervosa. Acta Psychiatr Scand 1994;90:397–398.

    External Resources

  21. Raphael FJ, Rodin DA, Peattie A, Bano G, Kent A, Nussey SS, Lacey JH: Ovarian morphology and insulin sensitivity in women with bulimia nervosa. Clin Endocrinol 1995;43:451–455.
  22. Gladue BA: Aggressive behavioral characteristics, hormones, and sexual orientation in men and women. Aggressive Behav 1991;17:313–326.
  23. Casas M, Alvarez E, Duro P: Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand 1986;73:221–222.

    External Resources

  24. Bergman L, Eriksson E: Marked symptom reduction in two women with bulimia nervosa treated with the testosterone receptor antagonist flutamide. Acta Psychiatr Scand 1996;94:137–139.

    External Resources

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00